COMP <GO>
IRWD vs ABBV // GROSS PROFIT MARGIN
Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: IRWD 6
— ABBV 5
■ METRIC PARITY
LAST: $3.62 (+0.28%) • MKT CAP: $598.2M
gross-margins
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRWD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRWD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 29.00% | +56.00 | IRWD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.9x | 33.3x | -29.40 | IRWD | /valuation <GO> |
| Free Cash Flow Yield | 21.23% | 3.47% | +17.76 | IRWD | /fcf-yield <GO> |
| Operating Margin | 33.30% | 24.60% | +8.70 | IRWD | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 6.90% | +1.20 | IRWD | /net-margins <GO> |
| Revenue Growth (YoY) | -15.70% | 8.60% | -24.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.5 | 65.1 | -24.59 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.2x | 113.1x | -89.90 | IRWD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $598.2M | $513.86B | -$513.26B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRWD REV | ABBV REV | IRWD GROSS % | ABBV GROSS % | IRWD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $296.2M | $61.16B | — | 70.2% | $127.0M | $17.82B |
| FY 2024 | $351.4M | $56.33B | — | 70.0% | $103.4M | $17.83B |
| FY 2023 | $442.7M | $54.32B | — | — | $183.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRWD // BETA —
ABBV // BETA 1.15